Compare QTRX & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QTRX | TTRX |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.0M | 281.2M |
| IPO Year | 2017 | N/A |
| Metric | QTRX | TTRX |
|---|---|---|
| Price | $3.55 | $7.99 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $6.00 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 562.3K | 125.6K |
| Earning Date | 05-06-2026 | 05-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $37,632,000.00 | N/A |
| Revenue This Year | $25.49 | N/A |
| Revenue Next Year | $10.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 64.52 | N/A |
| 52 Week Low | $2.40 | $2.57 |
| 52 Week High | $8.77 | $11.69 |
| Indicator | QTRX | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.57 | 48.25 |
| Support Level | $3.30 | $4.40 |
| Resistance Level | $3.81 | $10.48 |
| Average True Range (ATR) | 0.31 | 0.89 |
| MACD | -0.08 | -0.28 |
| Stochastic Oscillator | 5.26 | 10.85 |
Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and related consumables to research laboratories, contract research organizations (CROs), academic institutions, and bio-pharmaceutical companies, and provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, and SP-X Imaging and Analysis System. Geographically, it operates in North America, EMEA, and the Asia Pacific.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.